Literature DB >> 2163696

Human erythropoietin receptor: cloning, expression, and biologic characterization.

S S Jones1, A D D'Andrea, L L Haines, G G Wong.   

Abstract

We have isolated the human homologue of the murine erythropoietin receptor (mEPO-R) from an erythroleukemia line, OCIM1, and from fetal liver. Both the cDNA and protein sequence of the human receptor were 82% homologous to the mEPO-R. Heterologous expression of the human cDNA in COS cells yielded a protein of about 66 Kd. The protein could be specifically immunoprecipitated with either an antibody raised against the amino terminus of mEPO-R or by a monoclonal antibody that bound EPO bound to its receptor. Cross-linking of radioiodinated EPO to COS cells expressing the human EPO-R gave apparent molecular weights of 66 and 100 Kd for the receptor. The murine interleukin-3-dependent pre-B-lymphocyte cell line, Ba/F3, was made EPO-dependent by transfection of the human cDNA into the cells and selecting for growth in EPO-containing media.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2163696

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

1.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

2.  Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells.

Authors:  Emilia Stellacci; Antonella Di Noia; Angela Di Baldassarre; Giovanni Migliaccio; Angela Battistini; Anna Rita Migliaccio
Journal:  Exp Hematol       Date:  2009-05       Impact factor: 3.084

3.  Response to erythropoietin in erythroid subclones of the factor-dependent cell line 32D is determined by translocation of the erythropoietin receptor to the cell surface.

Authors:  A R Migliaccio; G Migliaccio; A D'Andrea; M Baiocchi; S Crotta; S Nicolis; S Ottolenghi; J W Adamson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

Review 4.  Erythropoietin receptor. Subunit structure and activation.

Authors:  A D D'Andrea; L I Zon
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

5.  Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family.

Authors:  M Murakami; M Narazaki; M Hibi; H Yawata; K Yasukawa; M Hamaguchi; T Taga; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

6.  Activation of the erythropoietin receptor promoter by transcription factor GATA-1.

Authors:  L I Zon; H Youssoufian; C Mather; H F Lodish; S H Orkin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

7.  A high-coverage genome sequence from an archaic Denisovan individual.

Authors:  Matthias Meyer; Martin Kircher; Marie-Theres Gansauge; Heng Li; Fernando Racimo; Swapan Mallick; Joshua G Schraiber; Flora Jay; Kay Prüfer; Cesare de Filippo; Peter H Sudmant; Can Alkan; Qiaomei Fu; Ron Do; Nadin Rohland; Arti Tandon; Michael Siebauer; Richard E Green; Katarzyna Bryc; Adrian W Briggs; Udo Stenzel; Jesse Dabney; Jay Shendure; Jacob Kitzman; Michael F Hammer; Michael V Shunkov; Anatoli P Derevianko; Nick Patterson; Aida M Andrés; Evan E Eichler; Montgomery Slatkin; David Reich; Janet Kelso; Svante Pääbo
Journal:  Science       Date:  2012-08-30       Impact factor: 47.728

8.  Characterization of mpl cytoplasmic domain sequences required for myeloproliferative leukemia virus pathogenicity.

Authors:  L Bénit; G Courtois; M Charon; P Varlet; I Dusanter-Fourt; S Gisselbrecht
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  Unregulated expression of the erythropoietin receptor gene caused by insertion of spleen focus-forming virus long terminal repeat in a murine erythroleukemia cell line.

Authors:  M Hino; A Tojo; Y Misawa; H Morii; F Takaku; M Shibuya
Journal:  Mol Cell Biol       Date:  1991-11       Impact factor: 4.272

10.  Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease.

Authors:  Eliyahu V Khankin; Walter P Mutter; Hector Tamez; Hai-Tao Yuan; S Ananth Karumanchi; Ravi Thadhani
Journal:  PLoS One       Date:  2010-02-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.